IPCI has 7 ANDAs awaiting FDA approval 4 of them exceed the 36 Month average approval time by many months means FDA approvals could come any day now . They have another two Mega Drugs called Rexista & Regabatin which are ready to enter Phase 3 later this year .
Float is around 10 M and they have a low Market Cap of just $66 M makes IPCI one of the most attractive Play in the US Biotech Sector .
This Low Float Gem has the Potential to run into Double Digits with FDA approvals which means Deep Profitability for IPCI .GL
Intellipharmaceutics (IPCI)
Market-Cap: $66 M
Cash: $7.2 M
Burn-Rate: $1.5 M per Quarter
Shares Out: 23.3 M
The company received approval of its first generic product, Focalin XR, in November 2013 and its marketing partner Par Pharmaceutics immediately launched the drug at the end of November 2013. The company has a total of seven controlled-release generic drugs that are awaiting FDA approval.